In Brief: Diatide
This article was originally published in The Gray Sheet
Executive Summary
Diatide: Medical imaging agent manufacturer completes enrollment of 269 patients in a Phase III pivotal trial of its P829 injectable imaging product for detection and localization of lung cancer, the firm reports Dec. 29. Diatide plans to submit in the second quarter a new drug application for P829, which is comprised of a small-molecule, synthetic peptide and a molecule of technetium-99m. A conventional gamma camera is used to detect the technetium-99m molecule after the peptide in the agent binds to the somatostatin receptor, which is a growth hormone present in some cancers, the firm explains. Nycomed licenses and distributes P829 in Europe, South Africa and certain countries in the Middle East...